Cargando…

Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness

PURPOSE: To investigate the role of serum inflammatory cytokines and vascular endothelial growth factor (VEGF) in diabetic retinopathy (DR) and evaluate their relationship with macular thickness measurements obtained with optical coherence tomography (OCT). METHODS: The study enrolled 28 healthy sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozturk, Banu Turgut, Bozkurt, Banu, Kerimoglu, Hurkan, Okka, Mehmet, Kamis, Umit, Gunduz, Kemal
Formato: Texto
Lenguaje:English
Publicado: Molecular Vision 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751798/
https://www.ncbi.nlm.nih.gov/pubmed/19784389
_version_ 1782172262924812288
author Ozturk, Banu Turgut
Bozkurt, Banu
Kerimoglu, Hurkan
Okka, Mehmet
Kamis, Umit
Gunduz, Kemal
author_facet Ozturk, Banu Turgut
Bozkurt, Banu
Kerimoglu, Hurkan
Okka, Mehmet
Kamis, Umit
Gunduz, Kemal
author_sort Ozturk, Banu Turgut
collection PubMed
description PURPOSE: To investigate the role of serum inflammatory cytokines and vascular endothelial growth factor (VEGF) in diabetic retinopathy (DR) and evaluate their relationship with macular thickness measurements obtained with optical coherence tomography (OCT). METHODS: The study enrolled 28 healthy subjects (Group 1), 31 patients without DR (Group 2), 49 patients with nonproliferative DR (Group 3), and 46 patients with proliferative DR (Group 4). Macular profile was assessed with Stratus OCT-3 and the serum concentrations of VEGF and interleukin-1α (IL-1α), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), macrophage inflammatory protein (MIP-1α), monocyte chemoattractant protein (MCP-1), and epidermal growth factor (EGF) were measured using multiplex bead immunoassay. RESULTS: The median value of the visual acuity was 20/20 (Groups 1 and 2), and 20/100 (Group 3), and 20/125 (Group 4). The median value of central subfield macular thickness was estimated as 165.50 μm in Group 1, 202.5 μm in Group 2, 318 μm in Group 3, and 310 μm in Group 4. The median serum VEGF level, which was 98.20 pg/ml in Group 1, demonstrated a progressive rise to 125.37 pg/ml in Group 2, to 153.07 pg/ml in Group 3, and to 149.12 pg/ml in Group 4. Statistical significance was found between all groups (p<0.05) except between Groups 3 and 4 (p=0.87). The median levels of IL-1α and IL-6 were zero in all groups. The median serum levels of IL-8, IL-10, MIP-1α, and EGF revealed a wide range within each group but no statistical significance between the groups (p>0.05). The median serum levels of IL-8, IL-10, MIP-1α, and EGF revealed a wide range within each group, however, no statistically significant relationship was found between the groups (p>0.05). The median values of the serum MCP-1 concentrations presented a statistically significant rise with the progression of DR (p=0.02). No correlation was found between macular thickness and serum cytokine and VEGF levels (p>0.05). CONCLUSIONS: Increased serum levels of VEGF and MCP-1 may act as a key regulator of DR and provide a potential tool for risk assessment in diabetic patients. Further studies that evaluate both vitreous and serum levels in various stages of DR are needed to provide a better understanding of the interaction between systemic and local inflammatory and angiogenic factors.
format Text
id pubmed-2751798
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-27517982009-09-25 Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness Ozturk, Banu Turgut Bozkurt, Banu Kerimoglu, Hurkan Okka, Mehmet Kamis, Umit Gunduz, Kemal Mol Vis Research Article PURPOSE: To investigate the role of serum inflammatory cytokines and vascular endothelial growth factor (VEGF) in diabetic retinopathy (DR) and evaluate their relationship with macular thickness measurements obtained with optical coherence tomography (OCT). METHODS: The study enrolled 28 healthy subjects (Group 1), 31 patients without DR (Group 2), 49 patients with nonproliferative DR (Group 3), and 46 patients with proliferative DR (Group 4). Macular profile was assessed with Stratus OCT-3 and the serum concentrations of VEGF and interleukin-1α (IL-1α), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), macrophage inflammatory protein (MIP-1α), monocyte chemoattractant protein (MCP-1), and epidermal growth factor (EGF) were measured using multiplex bead immunoassay. RESULTS: The median value of the visual acuity was 20/20 (Groups 1 and 2), and 20/100 (Group 3), and 20/125 (Group 4). The median value of central subfield macular thickness was estimated as 165.50 μm in Group 1, 202.5 μm in Group 2, 318 μm in Group 3, and 310 μm in Group 4. The median serum VEGF level, which was 98.20 pg/ml in Group 1, demonstrated a progressive rise to 125.37 pg/ml in Group 2, to 153.07 pg/ml in Group 3, and to 149.12 pg/ml in Group 4. Statistical significance was found between all groups (p<0.05) except between Groups 3 and 4 (p=0.87). The median levels of IL-1α and IL-6 were zero in all groups. The median serum levels of IL-8, IL-10, MIP-1α, and EGF revealed a wide range within each group but no statistical significance between the groups (p>0.05). The median serum levels of IL-8, IL-10, MIP-1α, and EGF revealed a wide range within each group, however, no statistically significant relationship was found between the groups (p>0.05). The median values of the serum MCP-1 concentrations presented a statistically significant rise with the progression of DR (p=0.02). No correlation was found between macular thickness and serum cytokine and VEGF levels (p>0.05). CONCLUSIONS: Increased serum levels of VEGF and MCP-1 may act as a key regulator of DR and provide a potential tool for risk assessment in diabetic patients. Further studies that evaluate both vitreous and serum levels in various stages of DR are needed to provide a better understanding of the interaction between systemic and local inflammatory and angiogenic factors. Molecular Vision 2009-09-19 /pmc/articles/PMC2751798/ /pubmed/19784389 Text en http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ozturk, Banu Turgut
Bozkurt, Banu
Kerimoglu, Hurkan
Okka, Mehmet
Kamis, Umit
Gunduz, Kemal
Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness
title Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness
title_full Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness
title_fullStr Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness
title_full_unstemmed Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness
title_short Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness
title_sort effect of serum cytokines and vegf levels on diabetic retinopathy and macular thickness
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751798/
https://www.ncbi.nlm.nih.gov/pubmed/19784389
work_keys_str_mv AT ozturkbanuturgut effectofserumcytokinesandvegflevelsondiabeticretinopathyandmacularthickness
AT bozkurtbanu effectofserumcytokinesandvegflevelsondiabeticretinopathyandmacularthickness
AT kerimogluhurkan effectofserumcytokinesandvegflevelsondiabeticretinopathyandmacularthickness
AT okkamehmet effectofserumcytokinesandvegflevelsondiabeticretinopathyandmacularthickness
AT kamisumit effectofserumcytokinesandvegflevelsondiabeticretinopathyandmacularthickness
AT gunduzkemal effectofserumcytokinesandvegflevelsondiabeticretinopathyandmacularthickness